PE20070647A1 - Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1) - Google Patents
Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1)Info
- Publication number
- PE20070647A1 PE20070647A1 PE2006001495A PE2006001495A PE20070647A1 PE 20070647 A1 PE20070647 A1 PE 20070647A1 PE 2006001495 A PE2006001495 A PE 2006001495A PE 2006001495 A PE2006001495 A PE 2006001495A PE 20070647 A1 PE20070647 A1 PE 20070647A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- alkylazethyl
- antagonists
- fluoro
- heterocicles
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 9
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 7
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 3-ALQUILAZETIDINA DE FORMULA (I) DONDE X ES HIDROXI, NH2, METILO O METOXI; R2 Y R3 SON CADA UNO H, METILO, TRIFLUOROMETILO, ENTRE OTROS; R8 ES H, HALOGENO, METILO, ENTRE OTROS; R9 ES H, F, CN, ENTRE OTROS; R10 ES H, CF3, CN, METILO, ENTRE OTROS. SON COMPUESTOS PRERERIDOS: 3-[(S)-(4-CLOROFENIL)(3-{(1S)-2-FLUORO-1-[3-FLUORO-5-(5-OXO-4,5-DIHIDRO-1,3,4-OXADIAZOL-2-IL)FENIL]-2-METILPROPIL}AZETIDIN-1-IL)METIL]BENZONITRILO, 3-[(S)-(4-CLOROFENIL)(3-{(1S)-2-FLUORO-1-[3-FLUORO-5-(1,3,4-OXADIAZOL-2-IL)FENIL]-2-METILPROPIL}AZETIDIN-1-IL)METIL]BENZONITRILO, 3-[(S)-(3-{(1S)-1-[3-(5-AMINO-1,3,4-OXADIAZOL-2-IL)-5-FLUOROFENIL]-2-FLUORO-2-METILPROPIL}AZETIDIN-1-IL)(4-CLOROFENIL)METIL]BENZONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CANABINOIDE 1 (CB1) SIENDO UTILES PARA EL TRATAMIENTO DE PSICOSIS, ENFERMEDAD DE ALZHEIMER, MIGRANA, NEUROPATIA, ESCLEROSIS MULTIPLE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070647A1 true PE20070647A1 (es) | 2007-08-11 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001495A PE20070647A1 (es) | 2005-11-28 | 2006-11-23 | Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1) |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (es) |
| KR (1) | KR20080073721A (es) |
| AR (1) | AR058199A1 (es) |
| BR (1) | BRPI0619018A2 (es) |
| CR (1) | CR10014A (es) |
| DO (1) | DOP2006000261A (es) |
| EC (1) | ECSP088477A (es) |
| IL (1) | IL191586A0 (es) |
| MA (1) | MA30086B1 (es) |
| NO (1) | NO20082919L (es) |
| PE (1) | PE20070647A1 (es) |
| RU (1) | RU2008126248A (es) |
| SV (1) | SV2009002917A (es) |
| TW (1) | TW200804317A (es) |
| WO (1) | WO2007062193A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) * | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009054923A2 (en) * | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| EP2611788B1 (en) | 2010-09-03 | 2017-04-12 | University of Florida Research Foundation, Incorporated | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| AU2004252109B2 (en) * | 2003-06-11 | 2010-04-08 | Merck Sharp & Dohme Corp. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| AU2006242219A1 (en) * | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/es unknown
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 TW TW095143274A patent/TW200804317A/zh unknown
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/ru not_active Application Discontinuation
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/pt not_active IP Right Cessation
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en not_active Ceased
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/ko not_active Withdrawn
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/es not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/es unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/es not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/es unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/es not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/fr unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0619018A2 (pt) | 2016-11-29 |
| ECSP088477A (es) | 2008-06-30 |
| TW200804317A (en) | 2008-01-16 |
| IL191586A0 (en) | 2008-12-29 |
| RU2008126248A (ru) | 2010-01-10 |
| SV2009002917A (es) | 2009-02-19 |
| CR10014A (es) | 2008-07-29 |
| MA30086B1 (fr) | 2008-12-01 |
| KR20080073721A (ko) | 2008-08-11 |
| DOP2006000261A (es) | 2007-07-15 |
| EP1954692A1 (en) | 2008-08-13 |
| NO20082919L (no) | 2008-08-27 |
| WO2007062193A1 (en) | 2007-05-31 |
| AR058199A1 (es) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20001483A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
| PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20090741A1 (es) | Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano | |
| PE20081229A1 (es) | Antagonistas de receptor de orexina de diazepam sustituido | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20061093A1 (es) | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 | |
| PE20080895A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20070004A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
| PE20081472A1 (es) | Compuestos de pirazolina | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20080056A1 (es) | Derivados de cromencarboxamida como antagonistas del receptor s1p1 | |
| PE20090160A1 (es) | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA | |
| NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| PE20120593A1 (es) | Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma | |
| PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
| PE20070647A1 (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos como antagonistas del receptor canabinoide 1 (cb1) | |
| PE20090592A1 (es) | Nuevos derivados de piperazina-amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |